STOCK TITAN
  1. Home
  2. Sec-filings
  3. LKFT
  4. [6-K] Lakefront Biotherapeutics NV Current Report (Foreign Issuer)

Lakefront buys back 125K shares for €3.0M

Lakefront Biotherapeutics repurchased 125,517 shares for about €3.0 million under its ongoing buyback program.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Lakefront Biotherapeutics NV (LKFT) reports that, under its share repurchase program announced on June 9, 2026, it bought back 125,517 ordinary shares between September 7 and September 11, 2026 through an independent financial intermediary across several European trading venues.

The repurchases were executed at an average price of €23.95 per share, for a total consideration of €3,005,545.12, with prices ranging from €23.20 to €24.56. As of market close on September 11, 2026, Lakefront held 1,418,855 of its own ordinary shares.

Positive

  • None.

Negative

  • None.

Filing Explained

The September 15 Form 6-K states that the report, including its repurchase exhibit, is incorporated by reference into Lakefront’s listed Form S-8 registration statements, extending this disclosure into those registration statements without reporting a new issuance or sale.

Shares repurchased 125,517 shares Total ordinary shares bought back between September 7 and September 11, 2026
Average repurchase price €23.95 per share Weighted average price paid during the September 7–11, 2026 buybacks
Total repurchase amount €3,005,545.12 Aggregate consideration for 125,517 shares repurchased September 7–11, 2026
Price range during repurchases €23.20–€24.56 per share Lowest and highest prices paid in the reported transactions
Treasury shares held 1,418,855 shares Lakefront ordinary shares held by the company as of market close on September 11, 2026
repurchase program financial
"Within the framework of the repurchase program announced on June 9, 2026"
A repurchase program is when a company buys back its own shares from the open market. This reduces the total number of shares available, which can increase the value of each remaining share and signal confidence in the company's future. For investors, it often suggests that the company believes its stock is undervalued and can be a sign of financial strength.
discretionary mandate financial
"it has repurchased 125,517 Lakefront shares via a discretionary mandate"
independent financial intermediary financial
"via a discretionary mandate to an independent financial intermediary"
BCMAxCD3 T‑cell engager medical
"anchored by gamgertamig, a potential first‑in‑class and best-in-class BCMAxCD3 T‑cell engager"
forward-looking statements regulatory
"This press release contains forward-looking statements within the meaning of"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did Lakefront Biotherapeutics (LKFT) repurchase in early September 2026?
Lakefront Biotherapeutics repurchased 125,517 ordinary shares between September 7 and September 11, 2026 under its previously announced share repurchase program.

What was the total amount spent by LKFT on the September 2026 share repurchases?
Lakefront Biotherapeutics spent a total of €3,005,545.12 to repurchase 125,517 shares between September 7 and September 11, 2026.

What was the average price paid per LKFT share in the September 2026 buybacks?
The average price paid per Lakefront Biotherapeutics share during the September 7–11, 2026 repurchase period was €23.95, with individual trade prices ranging from €23.20 to €24.56.

How many LKFT shares does Lakefront Biotherapeutics hold in treasury after these repurchases?
As of market close on September 11, 2026, Lakefront Biotherapeutics held 1,418,855 of its own ordinary shares following the reported buybacks.

On which markets did LKFT execute its September 2026 share repurchases?
Lakefront Biotherapeutics executed its September 7–11, 2026 share repurchases on XAMS, TQEX, CEUX, and AQEU under a discretionary mandate to an independent financial intermediary.

What program are the LKFT September 2026 buybacks part of?
The September 7–11, 2026 repurchases are part of Lakefront Biotherapeutics’ share repurchase program announced on June 9, 2026, under which it plans to repurchase its ordinary shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026

Commission File Number: 001-37384

Lakefront Biotherapeutics
(Translation of registrant's name into English)

Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).

On September 15, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit 99.1. Press release dated September 15, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Lakefront Biotherapeutics    
  (Registrant)
   
  
Date: September 15, 2026     /s/ Ying Deng    
  Ying Deng
  Authorized Officer
  

EXHIBIT 99.1

Acquisition of Own Shares

Mechelen, Belgium; 15 September 2026, 22.01 CET; regulated information

Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between September 07, 2026 and September 11, 2026 it has repurchased 125,517 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows:

Date of purchaseMarket/MTFNumber of sharesAverage price paid (€)Total (€)Lowest price paid (€)Highest price paid (€)
07/09/2026XAMS22,86124.44558,763.9924.2024.56
07/09/2026TQEX1,16624.4328,486.2024.2624.56
07/09/2026CEUX15724.473,842.4724.4424.56
08/09/2026XAMS23,62924.23572,611.0123.9824.52
08/09/2026TQEX1,70524.3341,475.6624.2824.38
08/09/2026CEUX2,04424.2349,533.6824.0024.40
08/09/2026AQEU49224.2611,937.8924.0624.36
09/09/2026XAMS22,01523.91526,444.6923.6424.12
09/09/2026TQEX52723.9012,596.5623.8224.02
09/09/2026CEUX2,35523.9556,410.7323.8424.10
09/09/2026AQEU91424.0121,941.2123.8624.08
10/09/2026XAMS20,28523.64479,622.6023.2423.96
10/09/2026TQEX82723.5619,487.0123.3023.92
10/09/2026CEUX1,91723.2844,631.2123.2623.34
10/09/2026AQEU98423.7823,395.1923.6823.92
11/09/2026XAMS20,03823.45469,987.2823.2023.66
11/09/2026TQEX49223.6211,619.4723.5223.64
11/09/2026CEUX2,64023.3861,727.9523.2023.60
11/09/2026AQEU46923.5211,030.3223.4423.62
Total 125,51723.953,005,545.1223.2024.56

As of market close on September 11, 2026, Lakefront holds 1,418,855 of its own ordinary shares.

About Lakefront Biotherapeutics
Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class and best-in-class BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.

For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com

Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,” “will,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “continue,” “should,” “encouraging,” “aim,” “progress,” “remain,” “explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation.

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases

Keep reading

More on LKFT

Trending in the feed

Open the live feed